SE inhibitors are being actively studied to combat oncological diseases, among which are BET, CDK7, and MYC inhibitors (for cancer types in which an abnormally high expression of the MYC gene is observed), as well as their combinations with chemotherapy (e.g., a combination therapy with cisplatin and JQ1 for cisplatin-resistant ovarian cancer has been suggested [183]). This evidence concerns the gene MYC and ovarian carcinoma.